{"id":"W3015569704","doi":"10.1136/bjophthalmol-2020-316195","title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","year":2020,"lang":"en","type":"review","venue":"British Journal of Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Moorfields Eye Hospital NHS Foundation Trust; Retina UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Moorfields Eye Charity; Wellcome Trust; Wellcome; Fight for Sight; Foundation Fighting Blindness","keywords":"Macular degeneration; Medicine; Clinical trial; Blindness; Genetic enhancement; Bevacizumab; Intensive care medicine; Ophthalmology; Optometry; Surgery; Pathology; Gene; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001545527,0.0002922961,0.003636572,0.0001246255,0.0001399936,0.00006989932,0.0001098354,0.0005276914,0.0003881099],"category_scores_gemma":[0.0008421386,0.0002402921,0.002642967,0.0001818418,0.0001069362,0.00006077181,0.00002200736,0.0005183603,0.000004686608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005367909,"about_ca_system_score_gemma":0.0005941825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004595138,"about_ca_topic_score_gemma":1.712444e-7,"domain_scores_codex":[0.9956677,0.001336583,0.00222226,0.0003550459,0.0002378362,0.0001805906],"domain_scores_gemma":[0.9972987,0.0005830867,0.001286341,0.00014812,0.0003344503,0.0003492742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002450452,0.0003353847,0.00006148072,0.0007408488,0.004499521,0.03467355,0.000005836992,2.717157e-7,8.399957e-7,0.00003118151,0.001049135,0.9583569],"study_design_scores_gemma":[0.00306688,0.001109326,0.0007309186,0.001324192,0.00424034,0.3206196,0.000003790234,0.000001594461,5.658272e-7,0.0001599634,0.6686177,0.0001251256],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002222453,0.9941475,0.00003060174,0.0004475723,0.001130968,0.001740597,0.000163402,0.000008734902,0.0001081334],"genre_scores_gemma":[0.00007153612,0.992706,0.002288537,0.00007024842,0.003835237,0.00009736582,0.0005605155,0.00005453267,0.0003160526],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9582318,"threshold_uncertainty_score":0.9798827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1706153088601673,"score_gpt":0.4571611162559829,"score_spread":0.2865458073958156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}